DUBLIN – Eighteen months after terminating its interest in Adocia SA's Biochaperone technology, Eli Lilly and Co. is paying $50 million up front to get it back, and it could hand over another $520 million in development, regulatory and commercial milestones linked to the progress of Adocia's ultra-fast-acting insulin formulation, Biochaperone Lispro. Read More
Juno Therapeutics Inc., of Seattle, priced its eagerly awaited initial public offering (IPO) of about 11 million shares of common stock at $24 each, generating $264 million – making it the largest U.S. biotech IPO in the last 15 years. Read More
Roche AG unit Genentech Inc. said top-line data from a phase III study of Kadcyla (ado-trastuzumab emtansine) failed to beat the standard of care, Herceptin (trastuzumab) and a taxane, in helping people with previously untreated advanced HER2-positive breast cancer live longer without their disease worsening. Read More
LONDON – The first PARP (poly ADP-ribose polymerase) inhibitor is poised for market after Astrazeneca plc's Lynparza (olaparib) cleared the final approval hurdle in Europe and – late Friday – in the U.S. Read More
SHANGHAI – China has announced that it will be initiating phase I trials for Ad5-Ebov, a recombinant adenoviral Ebola vaccine co-developed by the Bioengineering Institute of the Chinese Academy of Military Medical Sciences (AMMS) and vaccine start-up Tianjin Cansino Biotechnology Inc. Read More
WASHINGTON – Tissue engineering in its various forms might prove clinically useful more rapidly than the genomics and proteomics that drive so much research, but the manipulation of cells is known to carry with it a more or less unique set of hazards. Read More
Novogen Ltd., of Sydney, said it entered definitive agreements to issue securities to existing institutional investors in the U.S. in a private placement with gross proceeds of approximately A$1.75 million (US$1.4 million). Read More
Canopus Biopharma Inc., of Los Angeles, said it completed research confirming the the potential of "a well-established prescription drug first approved by the FDA in the early 1980s" to inhibit the replication of live Ebola virus in an in vitro study Read More
Janssen-Cilag International NV, of Beerse, Belgium, part of Johnson & Johnson, said the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of Velcade (bortezomib), in combination with Rituxan (rituximab, Biogen Idec Inc. and Roche AG), cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplantation. Read More
A team from Johns Hopkins University has identified the receptor responsible for allergic reactions to drugs, resulting in both a mouse model to study such reactions and a therapeutic target to possibly prevent them. Read More
